The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Fenofibrate Reduces Plasma Cholesteryl Ester Transfer From HDL to VLDL and Normalizes the Atherogenic, Dense LDL Profile in Combined Hyperlipidemia
Abstract
The effect of fenofibrate on plasma cholesteryl ester transfer protein (CETP) activity in relation to the quantitative and qualitative features of apoB- and apoA-I–containing lipoprotein subspecies was investigated in nine patients presenting with combined hyperlipidemia. Fenofibrate (200 mg/d for 8 weeks) induced significant reductions in plasma cholesterol (−16%; P <.01), triglyceride (−44%; P <.007), VLDL cholesterol (−52%; P =.01), LDL cholesterol (−14%; P <.001), and apoB (−15%; P <.009) levels and increased HDL cholesterol (19%; P =.0001) and apoA-I (12%; P =.003) levels. An exogenous cholesteryl ester transfer (CET) assay revealed a marked decrease (−26%; P <.002) in total plasma CETP-dependent CET activity after fenofibrate treatment. Concomitant with the pronounced reduction in VLDL levels (37%; P <.005), the rate of CET from HDL to VLDL was significantly reduced by 38% ( P =.0001), whereas no modification in the rate of cholesteryl ester exchange between HDL and LDL occurred after fenofibrate therapy. Combined hyperlipidemia is characterized by an asymmetrical LDL profile in which small, dense LDL subspecies (LDL-4 and LDL-5, d =1.039 to 1.063 g/mL) predominate. Fenofibrate quantitatively normalized the atherogenic LDL profile by reducing levels of dense LDL subspecies (−21%) and by inducing an elevation (26%; P <.05) in LDL subspecies of intermediate density (LDL-3, d =1.029 to 1.039 g/mL), which possess optimal binding affinity for the cellular LDL receptor. However, no marked qualitative modifications in the chemical composition or size of LDL particles were observed after drug treatment. Interestingly, the HDL cholesterol concentration was increased by fenofibrate therapy, whereas no significant change was detected in total plasma HDL mass. In contrast, the HDL subspecies pattern was modified as the result of an increase in the total mass (11.7%) of HDL 2a , HDL 3a , and HDL 3b ( d =1.091 to 1.156 g/mL) at the expense of reductions in the total mass (−23%) of HDL 2b ( d =1.063 to 1.091 g/mL) and HDL 3c ( d =1.156 to 1.179 g/mL). Such changes are consistent with a drug-induced reduction in CETP activity. In conclusion, the overall mechanism involved in the fenofibrate-induced modulation of the atherogenic dense LDL profile in combined hyperlipidemia primarily involves reduction in CET from HDL to VLDL together with normalization of the intravascular transformation of VLDL precursors to receptor-active LDLs of intermediate density.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffin, B. A., Freeman, D. J., Tait, G. W., Thomson, J., Caslake, M. J., Packard, C. J., & Shepherd, J. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90129-5 · Cited by 525
Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117717 · Cited by 410
Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia.
Mann, C. J., Yen, F. T., Grant, A. M., & Bihain, B. E. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115535 · Cited by 339
Dejager, S., Bruckert, E., & Chapman, M. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40756-4 · Cited by 237
Self-citationChapman, M. J., Laplaud, P. M., Luc, G., Forgez, P., Bruckert, E., Goulinet, S., & Lagrange, D. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38518-7 · Cited by 216
Self-citationEffects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia
Knopp, R. H., Brown, W. V., Dujovne, C. A., Farquhar, J. W., Feldman, E. B., Goldberg, A. C., Grundy, S. M., Lasser, N. L., Mellies, M. J., Palmer, R. H., et al. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90871-0 · Cited by 65
Cited by
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citationLipids and Lipoproteins in Patients With Type 2 Diabetes
Krauss, R. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1496 · Cited by 756
Rosenson, R. S., Brewer, H. B., Chapman, M. J., Fazio, S., Hussain, M. M., Kontush, A., Krauss, R. M., Otvos, J. D., Remaley, A. T., & Schaefer, E. J. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.155333 · Cited by 511
Self-citationGenome-Wide Association Study of Plasma Polyunsaturated Fatty Acids in the InCHIANTI Study
Tanaka, T., Shen, J., Abecasis, G. R., Kisialiou, A., Ordovas, J. M., Guralnik, J. M., Singleton, A., Bandinelli, S., Cherubini, A., Arnett, D., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000338 · Cited by 418
Lamarche, B. (1998) · JAMA · doi:10.1001/jama.279.24.1955 · Cited by 417
Metadata
- Authors
- Guérin, M., Bruckert, E., Dolphin, P. J., Turpin, G., & Chapman, M. J.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1996-06
- Volume
- 16
- Issue
- 6
- Pages
- 763-772
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2145666707
- Cited by
- 195
- References
- 6
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fenofibrate Reduces Plasma Cholesteryl Ester Transfer From HDL to VLDL and Normalizes the Atherogenic, Dense LDL Profile in Combined Hyperlipidemia. https://app.cochat.ai/papers/10.1161/01.atv.16.6.763
- The paper
- Guérin, M., Bruckert, E., Dolphin, P. J., Turpin, G., & Chapman, M. J. (1996). Fenofibrate Reduces Plasma Cholesteryl Ester Transfer From HDL to VLDL and Normalizes the Atherogenic, Dense LDL Profile in Combined Hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.16.6.763
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.